ABSTRACT OBJECTIVES This study sought to define the prevalence and prognostic impact of blood transfusions in contemporary percutaneous coronary intervention (PCI) practice.
A dvances in antiplatelet and antithrombotic therapy have improved outcomes in patients undergoing percutaneous coronary intervention (PCI) through a reduction in ischemic events, albeit at the expense of increased risk of bleeding complications. Major bleeding observed during PCI independently predicts mortality and major adverse cardiac events (MACE), and a recent meta-analysis demonstrated an independent 3-fold increase in both mortality and MACE events following a major bleed (1). Between 2.0% and 4.0% of all patients undergoing PCI receive a blood transfusion (2-5), often following major bleeding events, with previous studies reporting marked variation in the use of red blood cell transfusion among patients with acute coronary syndromes (6) and in patients undergoing PCI (5) . Whereas the presence of anemia is independently associated with an increase in cardiac mortality and myocardial infarction in patients with acute coronary syndromes or undergoing PCI (7, 8) , the optimal use of blood products in such patients remains controversial. National transfusion practice guidelines offer no recommendation for or against a liberal or restrictive transfusion threshold for such patients (9) . National PCI registries have demonstrated that patients with bleeding events receive blood transfusions across the spectrum of hemoglobin values with significant variation in practice (5) , and a single-center study showed that a large proportion of patients undergoing PCI received transfusion for indications outside of published guidelines (10) .
A previous meta-analysis of 10 studies including 203,665 patients reported that blood transfusion in the setting of acute myocardial infarction is associated with a 3-fold increase in all-cause mortality and a 2-fold increase in recurrent myocardial infarction (11) , although it included studies mainly of patients with acute coronary syndromes who did not undergo PCI and were managed medically, hence the applicability of the findings to patients undergoing PCI remains unclear. Defining the role of transfusion in patients undergoing PCI can inform clinical practice. There has not been a systematic review or meta-analysis of the prevalence and prognostic impact of blood transfusion in the setting of PCI. We have therefore undertaken a metaanalysis to systematically study the impact of blood transfusion in patients who have undergone PCI on mortality and MACE outcomes. In this metaanalysis, we provide an overview of the cohorts, evaluating the rates of blood transfusion events and systematically studying the differences in the prognostic impact of blood transfusion in patients undergoing PCI.
METHODS
ELIGIBILITY CRITERIA. Studies were selected of patients who underwent PCI reporting mortality or cardiovascular events among patients with and without blood transfusion with no restriction based on study design or the indication for PCI. Studies that did not report on transfusion and those that did not report either mortality or MACE were excluded. QUALITY ASSESSMENT. Risk of bias was assessed by considering ascertainment of transfusion, ascertainment of outcomes, baseline differences between the transfused and not transfused group, loss to followup, and use of adjustment in data analysis. Publication bias was assessed using funnel plots when there were >10 studies available in the meta-analysis and there was no evidence of substantial statistical heterogeneity (12) .
DATA ANALYSIS. The program RevMan (version 5.1.7, Nordic Cochrane Centre, Copenhagen, Denmark) was used to do random effects meta-analysis using the inverse variance method for pooled odds ratios.
Similarity was assumed between the odds ratio and other relative measures such as relative risk, rate ratios, or hazard ratios (HRs) because cardiovascular events and death were rare events (13 
Transfusion After PCI Figure 2B ). Transfusion and the risk of adverse outcomes at >1-year follow-up is shown in Figure 2C . 
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PUBLICATION BIAS. Publication bias was not assessed because there was only 1 analysis with more than 10 studies, and there was evidence of substantial statistical heterogeneity.
DISCUSSION
The optimal use of blood products in patients undergoing PCI remains controversial. To the best of our knowledge, the present analysis is the first to systematically review blood transfusion and its use in contemporary PCI practice and to study its prognostic impact. Our meta-analysis of 19 studies including more than 2 million patients with more than 54,000 transfusion events has shown that the mean prevalence of blood transfusions in contemporary PCI is 2.3% and is independently associated with a 3-fold increased risk of mortality and MACE events.
Furthermore, our data suggest a dose-dependent adverse influence on mortality.
Both our current analysis and previous reports of transfusion practice nationally (5) Meta-analysis of the risk of mortality, major adverse cardiac events (MACE), and the risk of adverse outcomes at 1 year or more associated with blood transfusions and the risk of mortality with the number of units of blood transfused. CI ¼ confidence interval; IV ¼ intravenous.
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Transfusion After PCI and Risk of Adverse Outcomes Values are OR (95% CI).
Abbreviations as in Table 2 . ORs and HRs are followed by (95% CI).
Abbreviations as in Table 2 .
Kwok et al. Table 3 ). It appears that blood transfusion has an adverse prognostic impact irrespective of whether this has been given in the setting of a bleeding complication and is independent to the degree of baseline anemia or hematocrit nadir, although its greatest prognostic value appears to be in those patients without a bleeding event.
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